Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Pipeline Analysis 2017 Health and Fitness

Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Pipeline Analysis 2017

BY James Lee • May 20, 2017
James Lee

James Lee

  • 341 Articles
  • 887 Views
  • Joined February 15, 2016

Chronic inflammatory demyelinating polyneuropathy pipeline is expected to grow in the next few years on account of increasing prevalence of the disease, which is noticed by progressive muscle weakness, loss of deep tendon reflexes, abnormal sensations, etc. According to a study conducted by American Association of Neuromuscular & Electrodiagnostic Medicine, around 40,000 people in the U.S. get affected from the disease, every year. High prevalence of chronic inflammatory demyelinating polyneuropathy is in turn compelling the government agencies and pharmaceutical companies to promote research and development activities for facilitating growth of the pipeline.

Explore Report at: https://www.psmarketresearch.com/market-analysis/chronic-inflammatory-demyelinating-polyneuropathy-therapeutics-pipeline-analysis

Chronic inflammatory demyelinating polyneuropathy is an inflammatory disorder, which affectsthe peripheral nervous system. The diseaseis caused due to the damage of fatty covering myelin sheath that covers and protects nerve fibers.Occurrence of the disease is more common in males as compared to females. Sometimes it is also called as “chronic relapsing polyneuropathy”,whichis closely related to guillain-barre syndrome, because in both the cases the nervous system gets affected. However, in both the cases, the symptoms are not the same for everyone, and can vary from person to person. Some of the common symptoms of the disease includefatigue, pain, weakness, numbness, etc.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/chronic-inflammatory-demyelinating-polyneuropathy-therapeutics-pipeline-analysis/toc-sample

In 2017, Mitsubishi Tanabe pharmaceutical provided license to Novartis Inc., to conduct clinical trials on fingolimod in Switzerland only. All the drugs (including “fingolimod”, “Hyqvia” & “I10E”) have the efficacy to treat chronic inflammatory demyelinating polyneuropathy.

Some of the companies having a pipeline of chronic inflammatory deyelinating polyneuropathy therapeutic include Shire Inc., LB Biotechnologies., Pfizer Inc., Novartis N.V., Eliy-lilly& Company, Gilead Sciences, Inc., Galapagos NV, Astellas Pharma, Abbvie, Inc., Bexalta US, Inc., Mitsubishi Tanabe Pharma Corporation.




About InwebArticles

InwebArticles brings to you creativity at its best. Expert writers and InWeb publishers have brought together a podium where only useful, genuine and media-enriched pages are posted.
More..

Contact us




Newsletter

Subscribe to newsletter